A new tardive dyskinesia survey reported fewer work and school disruptions among people taking INGREZZA. The supplied headline doesn’t include the survey’s size or detailed results.
Neurocrine Biosciences announced the survey results on November 5, 2026. The headline reports fewer disruptions among people with tardive dyskinesia who use INGREZZA (valbenazine) capsules. The available information doesn’t include the survey design, number of participants, comparison group, or numerical findings. Neurocrine shares closed at US$165.06, up 3.05% for the day.
Investor takeaway: The announcement describes a reported day-to-day impact associated with INGREZZA. But without more detail, investors can’t assess the size or context of the findings.
Neurocrine Biosciences Inc
NBIX.US
NBIX.US
Neurocrine Biosciences Inc
WealthAwesomeMarket cap
$16.66B
P/E
24.4x
52W high
$186.12
52W low
$122.14
1W change
+12.68%
Beta
0.33
Analyst Price Targets
Based on 29 analysts covering NBIX · as of Nov 9, 2026
Wall Street analysts forecast NBIX stock price to rise 26.4% over the next 12 months.
Consensus
Strong Buy4.59 / 5.00
Avg. Target
C$208.11
+26.4% Upside
Previously C$207.50 on Nov 5, 2026
Current Price
C$164.63
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NBIX's historical volatility
30-Day Vol
45.5%
Annualized
90-Day Vol
39.1%
Annualized
Trend (90d)
+36.8%
Annualized drift
90d Mean
C$187.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$172.00 | C$147.02 – C$201.23 |
| 60 trading days | C$179.70 | C$143.94 – C$224.36 |
| 90 trading days | C$187.75 | C$143.07 – C$246.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Shares closed at US$165.06, up 3.05%
Trading volume was 94,732 shares, compared with a 20-day average of 1,420,853. The supplied volume comparison is 1.06x.
Bull case
The survey headline reports fewer work and school disruptions, outcomes that may matter to people living with tardive dyskinesia.
Bear case
The supplied information doesn’t include the survey methods, participant count, numerical results, or comparison details. Investors can’t judge the strength or scope of the finding without them.
What happened: INGREZZA survey reports fewer disruptions
Neurocrine Biosciences announced new survey results on November 5 about tardive dyskinesia and INGREZZA (valbenazine) capsules. The headline says the survey found fewer work and school disruptions. But the available information doesn’t say how many people took part, how the survey measured disruptions, whether it used a control group, or how large the reported difference was. Without those details, the headline alone offers limited context.
The announcement concerns survey results. The supplied facts don’t indicate a new regulatory decision or a change to the medicine’s approved use. Investors can follow company updates on the Neurocrine Biosciences stock page.
What the numbers show: US$165.06 close, with below-average volume
Neurocrine shares closed at US$165.06, up 3.05% for the session. The supplied figures also show gains of 12.68% over one week, 14.75% over one month, and 3.54% year to date. These figures describe the share price; they don’t show that the survey announcement caused the gains.
Trading volume was 94,732 shares, compared with a 20-day average of 1,420,853. The supplied volume-to-average figure is 1.06x, which doesn’t match those raw figures. The stock closed within its stated 52-week range of US$122.14 to US$186.12. Market capitalization and valuation aren’t needed to assess the survey announcement.
What to watch next: survey detail and company context
The main question is whether Neurocrine shares the survey methods and numerical results, including the participant count, how disruptions were measured, and any comparison used. That information would help readers understand what “fewer” means and how widely the finding may apply.
The supplied facts don’t name a publication or presentation venue, or give a date for further disclosure. Investors can check later announcements on the NBIX company page and distinguish new survey evidence from unrelated company news.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
